Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Stage of Development | 8 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Therapy Area | 9 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Indication | 10 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Companies | 12 | 2 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Products under Development by Universities/Institutes | 14 | 2 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Companies Involved in Therapeutics Development | 21 | 4 |
| Chong Kun Dang Pharmaceutical Corp. | 21 | 1 |
| SynDevRx, Inc. | 22 | 1 |
| Takeda Pharmaceutical Company Limited | 23 | 1 |
| Zafgen Inc. | 24 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Drug Profiles | 25 | 17 |
| beloranib Drug Profile | 25 | 8 |
| Drugs to Inhibit Methionine Aminopeptidase 2 for Obesity Drug Profile | 33 | 1 |
| fumagillin Drug Profile | 34 | 1 |
| ligerin Drug Profile | 35 | 1 |
| lodamin Drug Profile | 36 | 1 |
| RSF-101 Drug Profile | 37 | 1 |
| SDX-7320 Drug Profile | 38 | 1 |
| Small Molecules to Inhibit MAP2 for Obesity Drug Profile | 39 | 1 |
| Small Molecules to Inhibit MetAP-II for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders Drug Profile | 40 | 1 |
| ZGN-839 Drug Profile | 41 | 1 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Dormant Projects | 42 | 2 |
| Methionine Aminopeptidase 2 (MAP 2 or Peptidase M 2 or eIF-2-a Associated p67 Homolog or EC 3.4.11.18) Featured News &Press Releases | 44 | 16 |
| Jun 11, 2016: Zafgen Presents New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Associations 76th Scientific Sessions | 44 | 2 |
| Apr 03, 2016: Zafgen Presents New Data from the Phase 3 bestPWS Study Evaluating Beloranib in Prader-Willi Syndrome at ENDO 2016 | 46 | 2 |
| Mar 28, 2016: Zafgen to Present Data from bestPWS Study of Beloranib in Prader-Willi Syndrome at ENDO 2016 | 48 | 1 |
| Feb 18, 2016: Zafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint | 49 | 1 |
| Jan 20, 2016: Zafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints | 50 | 2 |
| Dec 02, 2015: Zafgen Announces Beloranib IND Placed on Complete Clinical Hold | 52 | 1 |
| Dec 02, 2015: Zafgen Provides Clinical Update on Beloranib | 52 | 1 |
| Oct 22, 2015: Zafgen Announces Beloranib Program Update | 53 | 1 |
| Oct 16, 2015: Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials | 54 | 1 |
| Oct 14, 2015: Zafgen Issues Statement | 54 | 1 |
| Sep 30, 2015: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma | 55 | 1 |
| Sep 09, 2015: Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes | 55 | 1 |
| May 28, 2015: Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome | 56 | 1 |
| May 08, 2015: Zafgen Presents Positive Safety And Efficacy Data From Phase 2 Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015 | 57 | 1 |
| May 07, 2015: Zafgen Announces Oral And Poster Presentations At The 22nd European Congress On Obesity | 58 | 2 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |